Immune thrombocytopenic purpura (ITP) is an autoimmune condition characterized by low platelet count with mucocutaneous and other bleedings. Clinical manifestations may range from spontaneous formation of purpura and petechiae, especially on the extremities, to epistaxis, bleeding at the gums or menorrhagia, any of which occur usually if the platelet count is below 20,000 per μl. A very low count may result in the spontaneous formation of hematomas in the mouth or on other mucous membranes. Fatal complications, including subarachnoid or intracerebral, lower gastrointestinal or other internal bleeding can arise due to an extremely low count. Vaccines may induce ITP by several mechanisms. Vaccine-associated autoimmunity may stem not only from the antigen-mediated responses but also from other constituents of the vaccine, such as yeast proteins, adjuvants, and preservatives diluents. The most likely is through virally induced molecular mimicry. The binding of pathogenic autoantibodies to platelet and megakaryocytes may cause thrombocytopenia by different mechanisms, such as opsonization, direct activation of complement, or apoptotic pathways. The autoantibodies hypothesis is not sufficient to explain all ITP cases: In the anti-platelet antibody-negative cases, a complementary mechanism based on T cell immune-mediated mechanism has been suggested. In particular, T cell subsets seem dysregulated with an increased production of pro-inflammatory cytokines, as IFN-γ and TNF, and chemokines, as CXCL10. Vaccines are one of the most striking discoveries in human history that changed dramatically life expectancy. Nonetheless, the occurrence of adverse events and autoimmune phenomena has been described following vaccination, and ITP may represent one of this.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
McCrae K. Immune thrombocytopenia: no longer “idiopathic”. Cleve Clin J Med. 2011;78:358–73.
Schwartz RS. Immune thrombocytopenic purpura–from agony to agonist. N Engl J Med. 2007;357:2299–301.
Luiken GA, McMillan R, Lightsey AL, et al. Platelet-associated IgG in immune thrombocytopenic purpura. Blood. 1977;50:317–25.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.
Arkfeld DG, Weitz IC. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009;23:1239–49.
Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol. 2009;Suppl71:8–12.
Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91–6.
Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113:1231–40.
Yenicesu I, Yetgin S, Ozyürek E, Aslan D. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol. 2002;19:433–7.
De Mattia D, Del Vecchio GC, Russo G, et al. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol. 2010;123:96–109.
Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the general practice research database. Br J Haematol. 2010;149:855–64.
Shlamovitz GZ, Johar S. A case of Evans’ syndrome following influenza vaccine. J Emerg Med. 2013;44:e149–51.
Tishler M, Levy O, Amit-Vazina M. Immune thrombocytopenic purpura following influenza vaccination. Isr Med Assoc J. 2006;8:322–3.
Rondina MT, Brewster B, Grissom CK, et al. In vivo platelet activation in critically ill patients with primary 2009 influenza AH1N1. Chest. 2012;141:1490–5.
Armstrong SM, Darwish I, Lee WL. Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection. Virulence. 2013;4:537–42.
Shoenfeld Y, Agmon-Levin N. ‘ASIA’—autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4–8.
Olsson B, Ridell B, Jernås M, Wadenvik H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann Hematol. 2012;91:271–7.
Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost. 2013;11:605–14.
Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46:S2–14.
Okazaki N, Takeguchi M, Sonoda K, et al. Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpura. Vaccine. 2011;29:4878–80.
Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136:309–14.
Liu XG, Hou M. Immune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand. Semin Hematol. 2013;50:S89–99.
Catani L, Fagioli ME, Tazzari PL, et al. Dendritic cells of immune thrombocytopenic purpura ITP show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. 2006;34:879–87.
Yu H, Liu Y, Han J, et al. TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur J Haematol. 2011;86:67–74.
Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura ITP plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887–95.
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.
Gu D, Chen Z, Zhao H, et al. Th1 CXCL10 and Th2 CCL2 chemokine expression in patients with immune thrombocytopenia. Hum Immunol. 2010;71:586–91.
Sakakura M, Wada H, Tawara I, et al. Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120:187–93.
Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112:1325–8.
Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 2009;94:1326.
Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011;96:1560–4.
Cao J, Li XQ, Chen C, et al. Imbalance of Th17/Treg cells ratio in peripheral blood of patients with immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011;19:730–3.
Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–4.
Rinaldi M, Perricone C, Ortega-Hernandez OD, Perricone R, Shoenfeld Y. Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. Lupus. 2014;23:554–67.
Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus. 2009;18:1127–8.
Garbe E, Andersohn F, Bronder E, et al. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol. 2012;68:821–32.
Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database. Platelets. 2012;23:490–4.
Yasuda H, Nagata M, Moriyama H, et al. Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report. Diabet Med. 2012;29:88–9.
Mantadakis E, Farmaki E, Thomaidis S, Tsalkidis A, Chatzimichael A. A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence? J Pediatr Hematol Oncol. 2010;32:e227–9.
Tsuji T, Yamasaki H, Tsuda H. Refractory idiopathic thrombocytopenic purpura following influenza vaccination. Rinsho Ketsueki. 2009;50:577–9.
Mamori S, Amano K, Kijima H, Takagi I, Tajiri H. Thrombocytopenic purpura after the administration of an influenza vaccine in a patient with autoimmune liver disease. Digestion. 2008;77:159–60.
Granier H, Nicolas X, Laborde JP, Talarmin F. Severe autoimmune thrombopenia following anti-influenza vaccination. Presse Med. 2003;32:1223–4.
Jin CQ, Dong HX, Sun ZX, et al. Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine OPV. Hum Vaccin Immunother. 2013;9:1739–40.
Casoli P, Tumiati B. Acute idiopathic thrombocytopenic purpura after anti-influenza vaccination. Medicina Firenze. 1989;9:417–8.
Kelton JG. Vaccination-Associated relapse of immune thrombocytopenia. JAMA. 1981;245:369–70.
Brodin-Sartorius A, Guebre-Egziabher F, Fouque D, et al. Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse? Am J Kidney Dis. 2006;48:e31–4.
Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine. 2012;30:7123–9.
Huang WT, Huang WI, Huang YW, Hsu CW, Chuang JH. The reporting completeness of a passive safety surveillance system for pandemic H1N1 2009 vaccines: a capture-recapture analysis. Vaccine. 2012;30:2168–72.
Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol. 2005;169:31–8.
Tsang P, Gorse GJ, Strout CB, et al. Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Vaccine. 2014;32:2507–17.
Jin Cheng-Giang, Dong Hai-xin, Sun Zhuo-xiang, et al. Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine OPV. Hum Vaccin Immunother. 2013;9:1739–40.
Wang JD, Huang FL, Chen PY, Wang TM, Chi CS, Chang TK. Acute immune thrombocytopenic purpura in infants: associated factors, clinical features, treatment and long-term outcome. Eur J Haematol. 2006;77:334–7.
Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA. 2004;292:1702–10.
Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–93.
Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agomn-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants ASIA 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16.
Ronchi F, Cecchi P, Falcioni F, et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch Dis Child. 1998;78:273–4.
Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet. 1994;344:1293.
Meyboom RH, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines. Lancet. 1995;345:1638.
Neau D, Bonnet F, Michaud M, et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis. 1998;30:115–8.
Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295–301.
Polat A, Akca H, Dagdeviren E. Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey. Vaccine. 2008;26:6495–6.
Hsieh YL, Lin LH. Thrombocytopenic purpura following vaccination in early childhood: experience of a medical center in the past 2 decades. J Chin Med Assoc. 2010;73:634–7.
Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Saf. 2010;33:65–7.
O’Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129:248–55.
Sauvè LJ, Bettinger J, Scheifele D, et al. Postvaccination thrombocytopenia in Canada. Pediatr Infect Dis J. 2010;29:559–61.
Grimaldi-Bensouda L, Michel M, Aubrun E, et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood. 2012;120:4938–44.
Sharma SK, Seth T, Agrawal N, Mahapatra M, Mishra P. Immune thrombocytopenic purpura following anti-rabies vaccines. Platelets. 2012;23:317–8.
Benz R, Krause M, Taverna C. Immune thrombocytopenic purpura reactivation after tick-borne encephalitis vaccination. Vaccine. 2009;27:5172–3.
Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:340–98.
Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine. 2009;27:3690.
Szenborn L, Czajka H, Brzostek J, et al. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12–18 months of age. Pediatr Infect Dis J. 2013;32:777–85.
Drachtman RAl, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med. 1994;148:326–7.
Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics. 1996;97:738–9.
Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993;82:267–70.
Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system 1190–1994. Pediatr Infect Dis J. 1996;15:88–90.
Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84:227–9.
Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55:107–11.
Bibby AC, Farrell A, Cummins M, Erlewyn-Lajeunesse M. Is MMR immunisation safe in chronic idiopathic thrombocytopenic purpura? Arch Dis Child. 2008;93:354–5.
Stowe J, Kafatos G, Andrews N, Miller E. Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child. 2008;93:182–3.
British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;2003(120):574–96.
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, summary recommendations of the Advisory Committee on Immunization Practices ACIP. MMWR Recomm Rep. 2013;2013(62):1–34.
Ikegame K, Kaida K, Fujioka T, et al. Idiopathic thrombocytopenic purpura after influenza vaccination in a bone marrow transplantation recipient. Bone Marrow Transpl. 2006;38(4):323–4.
Yehuda Shoenfeld has served as an expert witness in cases involving adverse vaccine reaction in the no-fault U.S. National Vaccine Injury Compensation Program.
About this article
Cite this article
Perricone, C., Ceccarelli, F., Nesher, G. et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res 60, 226–235 (2014). https://doi.org/10.1007/s12026-014-8597-x
- Immune thrombocytopenic purpura
- Autoimmune diseases